Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 taletrectinib in ROS1-positive advanced or metastatic NSCLC and other solid tumors
jRCT2071210051Phase 2Active, not recruiting
- Sponsor
- Nuvation Bio
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of taletrectinib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms, sponsored by Nuvation Bio. Primary endpoint: Objective response rate. Started Sep 2021; status: active, not recruiting.
02
Drugs
taletrectinib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2071210051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210051.